PONTIAC (NT-proBNP selected prevention of cardiac eveNts in a population of diabetic patients without A history of cardiac disease): A prospective randomized controlled trial

Journal of the American College of Cardiology

Volumn 62, Issue 15, 2013, Pages 1365-1372

  Huelsmann, Martin ^a   Neuhold, Stephanie ^a   Resl, Michael ^a   Strunk, Guido ^b,c   Brath, Helmut ^d   Francesconi, Claudia ^e   Adlbrecht, Christopher ^a   Prager, Rudolf ^f   Luger, Anton ^a   Pacher, Richard ^a   Clodi, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b TU DORTMUND UNIVERSITY   (Germany)

^c Department of Statistics   (Austria)

^d Diabetes Outpatient Clinic   (Austria)

^e Diabetes Outpatient Clinic   (Austria)

^f Hietzing Hospital Vienna   (Austria)

Author keywords

beta blockers; diabetes mellitus; NT BNP selected; primary prevention; RAS antagonists

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HEART DEATH; HEART DISEASE; HEART PROTECTION; HIGH RISK PATIENT; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

ACE; ANGIOTENSIN-CONVERTING ENZYME; BETA-BLOCKERS; DIABETES MELLITUS; EGFR; ESTIMATED GLOMERULAR FILTRATION RATE; N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE; NT-BNP-SELECTED; NT-PROBNP; PRIMARY PREVENTION; RAS; RAS ANTAGONISTS; RENIN-ANGIOTENSIN SYSTEM;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; FEMALE; HEART DISEASES; HEART RATE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRIMARY PREVENTION; PROSPECTIVE STUDIES;

EID: 84885005521     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.05.069     Document Type: Article

References (27)

1. A. Patel, S. MacMahon, and J. Chalmers Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
2. W. Duckworth, C. Abraira, and T. Moritz Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
3. R.L. Frye, P. August, and M.M. Brooks A randomized trial of therapies for type 2 diabetes and coronary artery disease N Engl J Med 360 2009 2503 2515
4. The ORIGIN Trial Investigators Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 367 2012 319 328
5. P. Gaede, P. Vedel, N. Larsen, G.V.H. Jensen, H.-H. Parving, and O. Pedersen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
6. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
7. The Action to Control Cardiovascular Risk in Diabetes Study Group H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
8. H. Haller, S. Ito, and J.L. Izzo Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes N Engl J Med 364 2011 907 917
9. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
10. P.M. Nilsson ACCORD and risk-factor control in type 2 diabetes N Engl J Med 362 2010 1628 1630
11. M. Huelsmann, S. Neuhold, and G. Strunk NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus Eur Heart J 29 2008 2259 2264
12. S. Neuhold, M. Resl, and M. Huelsmann Repeat measurements of glycated haemoglobin A(1c) and N-terminal pro-B-type natriuretic peptide: divergent behaviour in diabetes mellitus Eur J Clin Invest 41 2011 1292 1298
13. M. Clodi, M. Resl, and S. Neuhold A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus Eur J Prev Cardiol 19 2012 944 951
14. P. Gaede, P. Hildebrandt, G. Hess, H.H. Parving, and O. Pedersen Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria Diabetologia 48 2005 156 163
15. Osterreichische Diabetes Gesellschaft Diabetes Mellitus. Guidelines for the practice. Revised and expanded 2007 edition Wien Klin Wochenschr 121 Suppl 5 2009 S1 S87
16. J.B. Buse, H.N. Ginsberg, and G.L. Bakris Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association Diabetes Care 30 2007 162 172
17. J.F. Mann, R.E. Schmieder, and M. McQueen Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
18. M.A. Bhalla, A. Chiang, and V.A. Epshteyn Prognostic role of b-type natriuretic peptide levels in patients with type 2 diabetes mellitus J Am Coll Cardiol 44 2004 1047 1052
19. A. Dawson, S. Jeyaseelan, A.D. Morris, and A.D. Struthers B-type natriuretic peptide as an alternative way of assessing total cardiovascular risk in patients with diabetes mellitus Am J Cardiol 96 2005 933 934
20. L. Tarnow, M.A. Gall, B.V. Hansen, P. Hovind, and H.H. Parving Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes Diabetologia 49 2006 2256 2262
21. P. Gaede, P. Vedel, H.H. Parving, and O. Pedersen Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study Lancet 353 1999 617 622
22. G. Savarese, P. Costanzo, and J.G. Cleland A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure J Am Coll Cardiol 61 2013 131 142
23. G. Grassi, G. Seravalle, and F. Quarti-Trevano Reinforcement of the adrenergic overdrive in the metabolic syndrome complicated by obstructive sleep apnea J Hypertens 28 2010 1313 1320
24. L. Frankenstein, M. Nelles, and M. Slavutsky Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents J Heart Lung Transplant 26 2007 1033 1039
25. J.G. Lainchbury, R.W. Troughton, and K.M. Strangman N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure. Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial J Am Coll Cardiol 55 2009 53 60
26. P. Jourdain, G. Jondeau, and F. Funck Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure. The STARS-BNP multicenter study J Am Coll Cardiol 49 2007 1733 1739
27. G.L. Bakris, and M.R. Weir Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160 2000 685 693